We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+7.34%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$14.8B
AUM Growth
+$2.13B
(+17%)
Cap. Flow
+$1.52B
Cap. Flow
% of AUM
10.28%
Top 10 Holdings %
Top 10 Hldgs %
17.14%
Holding
1,089
New
119
Increased
321
Reduced
473
Closed
155
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$132M |
| 2 |
Apple
AAPL
|
+$117M |
| 3 |
Microsoft
MSFT
|
+$100M |
| 4 |
Fidelity National Information Services
FIS
|
+$94.3M |
| 5 |
FedEx
FDX
|
+$91.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$97.2M |
| 2 |
Booking.com
BKNG
|
+$94.2M |
| 3 |
Phillips 66
PSX
|
+$82.9M |
| 4 |
Gilead Sciences
GILD
|
+$73.9M |
| 5 |
Snowflake
SNOW
|
+$51.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.09% |
| 2 | Financials | 15.5% |
| 3 | Healthcare | 14.12% |
| 4 | Consumer Discretionary | 11.36% |
| 5 | Industrials | 9.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
Usana Health Sciences
USNA
$419M
| $6.59M | 0.04% |
123,807
+4,091
| +3% | +$222K |
|
352
Rigel Pharmaceuticals
RIGL
$723M
| $6.48M | 0.04% |
432,247
+136,247
| +46% | +$1.25M |
|
353
American Vanguard Corp
AVD
$68.7M
| $6.4M | 0.04% |
294,685
+26,886
| +10% | +$599K |
|
354
Vanda Pharmaceuticals
VNDA
$304M
| $6.28M | 0.04% |
850,345
-5,625
| -0.7% | -$54.8K |
|
355
APA Corp
APA
$13B
| $6.26M | 0.04% |
134,013
-88,792
| -40% | -$3.97M |
|
356
IQVIA
IQV
$40.7B
| $6.2M | 0.04% |
30,253
+20,499
| +210% | +$4.16M |
|
357
Kforce
KFRC
$1.05B
| $6.18M | 0.04% |
112,792
-6,146
| -5% | -$355K |
|
358
Edgewell Personal Care
EPC
$1.3B
| $6.14M | 0.04% |
159,442
-3,227
| -2% | -$128K |
|
|
VMEO
359
DELISTED
Vimeo
VMEO
| $6.08M | 0.04% |
1,773,617
-428,660
| -19% | -$1.66M |
|
360
Codexis
CDXS
$158M
| $6.07M | 0.04% |
1,302,593
-25,075
| -2% | -$137K |
|
361
Coherus Oncology
CHRS
$217M
| $6.05M | 0.04% |
763,402
+191,555
| +33% | +$1.47M |
|
362
Idacorp
IDA
$8B
| $6M | 0.04% |
55,604
+7,612
| +16% | +$789K |
|
|
VRNT
363
DELISTED
Verint Systems
VRNT
| $5.99M | 0.04% |
165,182
-154,152
| -48% | -$5.56M |
|
364
REX American Resources
REX
$1.39B
| $5.95M | 0.04% |
373,804
-38,374
| -9% | -$578K |
|
|
TBI
365
Trueblue
TBI
$227M
| $5.86M | 0.04% |
299,371
-80,202
| -21% | -$1.63M |
|
366
Nektar Therapeutics
NKTR
$2.39B
| $5.81M | 0.04% |
171,390
+102,195
| +148% | +$4.95M |
|
367
Organon & Co
OGN
$3.56B
| $5.72M | 0.04% |
204,729
-172,433
| -46% | -$4.41M |
|
368
Paysafe
PSFE
$443M
| $5.65M | 0.04% |
406,612
+355,696
| +699% | +$5.75M |
|
369
NETGEAR
NTGR
$612M
| $5.64M | 0.04% |
311,553
-127,961
| -29% | -$2.52M |
|
370
W&T Offshore
WTI
$525M
| $5.64M | 0.04% |
1,010,437
+288,675
| +40% | +$1.99M |
|
371
Banc of California
BANC
$2.87B
| $5.62M | 0.04% |
352,700
+13,168
| +4% | +$215K |
|
|
FARO
372
DELISTED
Faro Technologies
FARO
| $5.59M | 0.04% |
190,103
+20,473
| +12% | +$608K |
|
373
Northwest Natural Holdings
NWN
$2.15B
| $5.58M | 0.04% |
117,309
-27,611
| -19% | -$1.29M |
|
374
Vicor
VICR
$8.33B
| $5.52M | 0.04% |
102,708
+1,899
| +2% | +$99.9K |
|
375
DuPont de Nemours
DD
$18.6B
| $5.52M | 0.04% |
64,030
-81,642
| -56% | -$6.52M |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q4 2022 Portfolio in Review
As of Q4 2022, Jacobs Levy Equity Management held 1,089 positions worth $14.8B, up 17% from $12.6B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Jacobs Levy Equity Management deployed $1.52B of net new capital in Q4 2022, opening 119 new positions and adding to 321 existing holdings. Its largest new stake was Fidelity National Information Services: 1,326,663 shares worth $90M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 26% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Booking.com, an estimated $94.2M trimmed.
- Jacobs Levy Equity Management's largest Q4 2022 buy was Fidelity National Information Services: 1,326,663 shares worth $90M.
- Jacobs Levy Equity Management added most to Vertex Pharmaceuticals in Q4 2022, an estimated $132M increase.
- Jacobs Levy Equity Management's biggest Q4 2022 reduction was Booking.com, cutting an estimated $94.2M.
- Jacobs Levy Equity Management fully exited Cigna in Q4 2022, selling an estimated $97.2M.
- Jacobs Levy Equity Management's ten largest holdings make up 17% of its $14.8B portfolio in Q4 2022.
- Jacobs Levy Equity Management opened 119 new positions and closed 155 in Q4 2022.
- Jacobs Levy Equity Management's portfolio value rose 17% quarter-over-quarter to $14.8B.
Based on Jacobs Levy Equity Management's 13F filing for Q4 2022, filed 14 Feb 2023.